ICB - Israel China Biotechnology Investments Ltd (TASE: ICB)

ICB - Israel China Biotechnology Investments Ltd (TASE: ICB) is rated 3 out of 5 in the category investment management. Read and write reviews about ICB - Israel China Biotechnology Investments Ltd (TASE: ICB).   ICB- Israel China Biotechnology Investments Ltd, specializes in investing and developing Israeli biomedical companies with potential in the Chinese market. It focuses on high-tech projects investment in Israel and committed to become China-Israel biomedical field’s “Alibaba”. ICB has a holey owned subsidiary- BSP Medical and its engineering facilities in Israel and prominent partners in China- CIB company, that fully operates in the the Municipal Government High-Tech Zone in Changsha, China. CIB has over 14 years of experience in the Chinese healthcare system and around 4 billion USD proven investment record for stock price increase. Together with CIB we provide the best investment platform for Israel leading medical device companies. We understand the Chinese medical market and its trends from within and work with you through the entire process- identify unique business opportunities, engineering upgrades, preliminary CFDA and production in China under risk-free conditions.